
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and ...
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated with elafibranor versus placebo showed …